Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-018-6898-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epigenetic Role of Long Non-coding RNAs in Multiple Myeloma.
Curr Oncol Rep
January 2025
Department of Molecular Oncology, Cancer Institute (WIA), Chennai, TN, India.
Purpose Of The Review: This review aims to explore the pivotal role of long non-coding RNAs (lncRNAs) as epigenetic regulators in the pathogenesis of multiple myeloma (MM). Additionally, we have portrayed the dual role of lncRNAs in the epigenetic landscape of MM pathobiology.
Recent Findings: In MM, lncRNAs are pivotal for proliferation, progression, and drug resistance by acting as miRNA sponges, regulating mRNA activity through microRNA recognition elements (MREs).
ASO Visual Abstract: Outcomes of Salvage Surgery for Esophageal Carcinoma: A Nationwide Cohort Study from the Dutch Upper GI Cancer Audit.
Ann Surg Oncol
January 2025
Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands.
ASO Author Reflections: CD45RO-Positive Memory T Cell Density in the Tumoral Core and Invasive Margin as an Immune-Related Prognostic Marker in Esophageal Squamous Cell Carcinoma.
Ann Surg Oncol
January 2025
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita City, Osaka, Japan.
ASO Visual Abstract: Ultrasound Visualization of the Recurrent Laryngeal Nerve-A Prospective Clinical Validation Study.
Ann Surg Oncol
January 2025
Department of Ultrasound, Peking University Third Hospital, Beijing, China.
Discovery and characterization of stereodefined PMO-gapmers targeting tau.
Mol Ther Nucleic Acids
March 2025
Eisai Inc., 35 Cambridgepark Drive, Cambridge, MA 02140, USA.
Antisense oligonucleotides (ASOs) are an important class of therapeutics to treat genetic diseases, and expansion of this modality to neurodegenerative disorders has been an active area of research. To realize chronic administration of ASO therapeutics to treat neurodegenerative diseases, new chemical modifications that improve activity and safety profiles are still needed. Furthermore, it is highly desirable to develop a single stereopure ASO with a defined activity and safety profile to avoid any efficacy and safety concerns due to the batch-to-batch variation in the composition of diastereomers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!